Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2128
mi
from 91732
Ocala, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2128
mi
from 91732
Ocala, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2180
mi
from 91732
Port Charlotte, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2180
mi
from 91732
Port Charlotte, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1707
mi
from 91732
Hoffman Estates, IL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1707
mi
from 91732
Hoffman Estates, IL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1881
mi
from 91732
Lexington, KY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2288
mi
from 91732
Columbia, MD
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2288
mi
from 91732
Columbia, MD
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1505
mi
from 91732
Golden Valley, MN
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1505
mi
from 91732
Golden Valley, MN
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1300
mi
from 91732
Omaha, NE
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1300
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2437
mi
from 91732
Albany, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2437
mi
from 91732
Albany, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2319
mi
from 91732
Syracuse, NY
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2319
mi
from 91732
Syracuse, NY
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1938
mi
from 91732
Toledo, OH
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1938
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2356
mi
from 91732
Allentown, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2356
mi
from 91732
Allentown, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2364
mi
from 91732
Upland, PA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2364
mi
from 91732
Upland, PA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2208
mi
from 91732
Charlottesville, VA
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2208
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2315
mi
from 91732
Fort Lauderdale, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
2130
mi
from 91732
Saint Petersburg, FL
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
2130
mi
from 91732
Saint Petersburg, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Margolin Brain Institute
216
mi
from 91732
Fresno, CA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Margolin Brain Institute
216
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
The Parkinson's Institute in Sunnyvale
320
mi
from 91732
Sunnyvale, CA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
The Parkinson's Institute in Sunnyvale
320
mi
from 91732
Sunnyvale, CA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Charlotte Neurological Services
2183
mi
from 91732
Port Charlotte, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Charlotte Neurological Services
2183
mi
from 91732
Port Charlotte, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
University Health Systems
214
mi
from 91732
Las Vegas, NV
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
University Health Systems
214
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Parkinson's Disease and Movement Disorders Center of Long Island
2470
mi
from 91732
Commack, NY
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Parkinson's Disease and Movement Disorders Center of Long Island
2470
mi
from 91732
Commack, NY
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Kingston Neurological Associates
2427
mi
from 91732
Kingston, NY
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Kingston Neurological Associates
2427
mi
from 91732
Kingston, NY
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
University Neurology, Inc
1879
mi
from 91732
Cincinnati, OH
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
University Neurology, Inc
1879
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Sentara Neurological Associates
2350
mi
from 91732
Virginia Beach, VA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Sentara Neurological Associates
2350
mi
from 91732
Virginia Beach, VA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Booth Gardner Parkinson's Care Center
967
mi
from 91732
Kirkland, WA
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Booth Gardner Parkinson's Care Center
967
mi
from 91732
Kirkland, WA
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
UM Movement Disorders Center
2322
mi
from 91732
Miami, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
UM Movement Disorders Center
2322
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
USF Parkinson's & Movement Disorders Center
2135
mi
from 91732
Tampa, FL
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
USF Parkinson's & Movement Disorders Center
2135
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
QUEST Research Institute
1956
mi
from 91732
Bingham Farms, MI
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
QUEST Research Institute
1956
mi
from 91732
Bingham Farms, MI
Click here to add this to my saved trials
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated:  9/12/2017
Hôpital Gabriel Montpied-Service de Neurologie A-
5810
mi
from 91732
Clermont-Ferrand Cedex 1,
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease
Status: Enrolling
Updated: 9/12/2017
Hôpital Gabriel Montpied-Service de Neurologie A-
5810
mi
from 91732
Clermont-Ferrand Cedex 1,
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Colorado Denver
825
mi
from 91732
Aurora, CO
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Colorado Denver
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Illinois at Chicago
1729
mi
from 91732
Chicago, IL
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Illinois at Chicago
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated:  9/12/2017
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Study in Parkinson's Disease of Exercise
Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease
Status: Enrolling
Updated: 9/12/2017
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated:  9/12/2017
Xenoscience Inc.
343
mi
from 91732
Phoenix, AZ
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated: 9/12/2017
Xenoscience Inc.
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated:  9/12/2017
Compass Research LLC
2184
mi
from 91732
Orlando, FL
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
Status: Enrolling
Updated: 9/12/2017
Compass Research LLC
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD
Status: Enrolling
Updated:  9/27/2017
Universtiy of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory
1931
mi
from 91732
Ann Arbor, MI
Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD
Status: Enrolling
Updated: 9/27/2017
Universtiy of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory
1931
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Effects of Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Status: Enrolling
Updated:  9/28/2017
NYIT
2453
mi
from 91732
Old Westbury, NY
Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Effects of Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease
Status: Enrolling
Updated: 9/28/2017
NYIT
2453
mi
from 91732
Old Westbury, NY
Click here to add this to my saved trials
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease
Status: Enrolling
Updated:  10/2/2017
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease
Status: Enrolling
Updated: 10/2/2017
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Treatment of Executive Dysfunction in Parkinson's Disease
Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study
Status: Enrolling
Updated:  10/2/2017
Johns Hopkins Hospital
2302
mi
from 91732
Baltimore, MD
Treatment of Executive Dysfunction in Parkinson's Disease
Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study
Status: Enrolling
Updated: 10/2/2017
Johns Hopkins Hospital
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
COPE-Co-morbidities, Parkinson's Disease and Exercise
COPE-Co-morbidities, Parkinson's Disease and Exercise
Status: Enrolling
Updated:  10/6/2017
OHSU
827
mi
from 91732
Portland, OR
COPE-Co-morbidities, Parkinson's Disease and Exercise
COPE-Co-morbidities, Parkinson's Disease and Exercise
Status: Enrolling
Updated: 10/6/2017
OHSU
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
330
mi
from 91732
Sun City, AZ
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
330
mi
from 91732
Sun City, AZ
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials